ATE204466T1 - Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung - Google Patents
Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellungInfo
- Publication number
- ATE204466T1 ATE204466T1 AT96921197T AT96921197T ATE204466T1 AT E204466 T1 ATE204466 T1 AT E204466T1 AT 96921197 T AT96921197 T AT 96921197T AT 96921197 T AT96921197 T AT 96921197T AT E204466 T1 ATE204466 T1 AT E204466T1
- Authority
- AT
- Austria
- Prior art keywords
- glass
- pct
- active agent
- production
- forming carrier
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 5
- 238000007496 glass forming Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000004014 plasticizer Substances 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Processing Of Solid Wastes (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502244A SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | A composition and a process for the preparation thereof |
| PCT/SE1996/000806 WO1997000670A1 (en) | 1995-06-20 | 1996-06-19 | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE204466T1 true ATE204466T1 (de) | 2001-09-15 |
Family
ID=20398685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96921197T ATE204466T1 (de) | 1995-06-20 | 1996-06-19 | Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6083518A (de) |
| EP (1) | EP0833611B1 (de) |
| JP (1) | JP4020331B2 (de) |
| AT (1) | ATE204466T1 (de) |
| AU (1) | AU695622B2 (de) |
| CA (1) | CA2225286C (de) |
| DE (2) | DE833611T1 (de) |
| DK (1) | DK0833611T3 (de) |
| ES (1) | ES2118677T3 (de) |
| NZ (1) | NZ311208A (de) |
| PT (1) | PT833611E (de) |
| SE (1) | SE9502244D0 (de) |
| WO (1) | WO1997000670A1 (de) |
| ZA (1) | ZA965237B (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136814A (en) * | 1997-12-08 | 2000-10-24 | Fujisawa Usa, Inc. | Aqueous acyclovir product |
| SE9801705D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| SE9801704D0 (sv) * | 1998-05-14 | 1998-05-14 | Bioglan Ab | Biologically active composition |
| EP1216037A2 (de) * | 1999-09-21 | 2002-06-26 | Emory University | Verfahren und zusammensetzungen zur behandlung von bluttplätchen-zusammenhängenden krankheiten, mit mpl hemmenden agenten |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| WO2001034119A2 (en) * | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| JP4512700B2 (ja) * | 2003-06-02 | 2010-07-28 | トーアエイヨー株式会社 | アシクロビル含有水溶液製剤 |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| AU2005245338B2 (en) | 2004-04-08 | 2011-11-17 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| ES2812250T3 (es) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
| GB2432528B (en) * | 2005-11-29 | 2011-04-06 | Ian Ripley | Anti-viral compositions comprising flavanone glycosides and fruit acids |
| AU2006339842B2 (en) * | 2006-03-08 | 2012-06-07 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
| EP2005959B1 (de) | 2006-03-08 | 2015-01-21 | Nihon Nohyaku Co., Ltd. | Pharmazeutische zusammensetzung zur ausserlichen verwendung |
| NZ571818A (en) * | 2006-03-08 | 2011-10-28 | Nihon Nohyaku Co Ltd | External pharmaceutical composition comprising luliconazole and an alpha-hydroxycarboxylic acid such as lactic acid, glycolic acid or malic acid. |
| EP2457560A1 (de) | 2006-06-14 | 2012-05-30 | Dr Reddy's Laboratories Limited | Topische Zusammensetzungen |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| KR100721126B1 (ko) | 2006-12-28 | 2007-05-23 | (주)바이오앤에이치엔티 | 모기 기피제 조성물 |
| PL2191828T3 (pl) * | 2007-09-05 | 2017-02-28 | Pola Pharma Inc. | Przeciwgrzybicza kompozycja farmaceutyczna |
| US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
| CN101808638B (zh) * | 2007-09-05 | 2012-07-25 | 宝丽制药股份有限公司 | 抗真菌组合物 |
| JP5411141B2 (ja) | 2007-09-10 | 2014-02-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| WO2009123183A1 (ja) | 2008-03-31 | 2009-10-08 | 国立大学法人広島大学 | 抗ウイルス剤および抗ウイルス用組成物 |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| CA2734500A1 (en) | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| HUE032022T2 (en) | 2009-01-09 | 2017-08-28 | Egyt Gyogyszervegyeszeti Gyar | Medicinal product with improved effect |
| JP5654497B2 (ja) | 2009-02-13 | 2015-01-14 | トピカ ファーマシューティカルズ，インコーポレイテッド | 抗真菌製剤 |
| KR101409792B1 (ko) | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | 항진균성 약제학적 조성물 |
| WO2010117089A2 (en) | 2009-04-09 | 2010-10-14 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| ES2602475T3 (es) | 2010-04-15 | 2017-02-21 | Tracon Pharmaceuticals, Inc. | Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER |
| HUE029570T2 (en) | 2010-04-27 | 2017-03-28 | Calcimedica Inc | Intracellular calcium modifying compounds |
| EP2563759B1 (de) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Verbindungen als modulatoren von intrazellulärem calcium |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| CN103180316A (zh) | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP3249054A1 (de) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulierungen und verfahren zur stabilisierung von pcr-reagenzien |
| WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP3077388A1 (de) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Hemmer der bruton-tyrosinkinase |
| CN106535889A (zh) | 2014-02-10 | 2017-03-22 | 帕塔拉制药有限责任公司 | 用于治疗肺疾病的肥大细胞稳定剂 |
| CA2938994A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Inhalable formulations of sodium cromolyn with improved bioavailability |
| WO2015164213A1 (en) | 2014-04-23 | 2015-10-29 | The Research Foundation For The State University Of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
| WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
| US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| KR102629269B1 (ko) | 2015-02-27 | 2024-01-24 | 커타나 파마슈티칼스, 인크. | Olig2 활성의 억제 |
| EP3331522A1 (de) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| KR102589056B1 (ko) | 2015-12-08 | 2023-10-12 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| US10821105B2 (en) | 2016-05-25 | 2020-11-03 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| KR102605329B1 (ko) | 2016-08-26 | 2023-11-22 | 커타나 파마슈티칼스, 인크. | Olig2 활성의 억제 |
| EP3506893A4 (de) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| US11382897B2 (en) | 2017-11-07 | 2022-07-12 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| JP7414282B2 (ja) | 2017-12-07 | 2024-01-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｎｓｄファミリー阻害物質及びそれによる治療の方法 |
| US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
| EP4155293B1 (de) | 2018-06-07 | 2025-07-30 | The Regents of The University of Michigan | Prc1-inhibitoren und verfahren zur behandlung damit |
| CA3107433A1 (en) | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
| GB2591681A (en) | 2018-08-29 | 2021-08-04 | Ftf Pharma Private Ltd | Methotrexate pharmaceutical composition |
| US12246042B2 (en) | 2018-08-29 | 2025-03-11 | Myos Corp. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| US12251405B2 (en) | 2018-10-03 | 2025-03-18 | Myos Corp. | Spray dried follistatin product |
| NL2021864B1 (en) * | 2018-10-24 | 2020-05-13 | Seranovo B V | Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations |
| JP2022509479A (ja) * | 2018-10-24 | 2022-01-20 | セラノヴォ・ベー・フェー | 経口医薬製剤のための深共晶溶媒プラットフォーム |
| WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
| JP7536767B2 (ja) | 2018-12-31 | 2024-08-20 | バイオメア フュージョン，インコーポレイテッド | メニン－ｍｌｌ相互作用の不可逆的阻害剤 |
| WO2020160113A1 (en) | 2019-02-01 | 2020-08-06 | Myos Rens Technology Inc. | Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals |
| AU2020240015B2 (en) | 2019-03-15 | 2025-10-09 | Unicycive Therapeutics Inc. | Nicorandil derivatives |
| EP4178571A4 (de) | 2020-07-10 | 2024-07-17 | The Regents Of The University Of Michigan | Gas41-inhibitoren und verfahren zu ihrer verwendung |
| WO2022133064A1 (en) | 2020-12-16 | 2022-06-23 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| US20240409558A1 (en) | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| US20250353854A1 (en) | 2022-06-03 | 2025-11-20 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| AU2023363975A1 (en) | 2022-10-19 | 2025-05-22 | Myos Corp. | Myogenic compounds |
| US20250002458A1 (en) | 2023-05-24 | 2025-01-02 | Unicycive Therapeutics Inc. | Salt forms of nicorandil derivative |
| WO2024249950A1 (en) | 2023-06-02 | 2024-12-05 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| WO2025072556A1 (en) | 2023-09-26 | 2025-04-03 | Unicycive Therapeutics, Inc. | Amino acid prodrugs of nicorandil |
| WO2025194102A1 (en) | 2024-03-15 | 2025-09-18 | Unicycive Therapeutics, Inc. | Pyridine modified nicorandil derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US33221A (en) * | 1861-09-03 | Improvement in soap | ||
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| USRE33221E (en) | 1982-04-29 | 1990-05-22 | American Dental Association Health Foundation | Dental restorative cement pastes |
| US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
| US4938964A (en) * | 1987-12-09 | 1990-07-03 | Showa Denko Kabushiki Kaisha | External dermatological composition |
| US5215757A (en) * | 1991-03-22 | 1993-06-01 | The Procter & Gamble Company | Encapsulated materials |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| DK0617612T3 (da) * | 1991-12-18 | 1998-04-14 | Warner Lambert Co | Fremgangsmåde til fremstilling af en fast dispersion |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
-
1995
- 1995-06-20 SE SE9502244A patent/SE9502244D0/xx unknown
-
1996
- 1996-06-19 AT AT96921197T patent/ATE204466T1/de active
- 1996-06-19 DE DE0833611T patent/DE833611T1/de active Pending
- 1996-06-19 ES ES96921197T patent/ES2118677T3/es not_active Expired - Lifetime
- 1996-06-19 AU AU62473/96A patent/AU695622B2/en not_active Expired
- 1996-06-19 NZ NZ311208A patent/NZ311208A/xx not_active IP Right Cessation
- 1996-06-19 JP JP50378997A patent/JP4020331B2/ja not_active Expired - Lifetime
- 1996-06-19 DK DK96921197T patent/DK0833611T3/da active
- 1996-06-19 DE DE69614689T patent/DE69614689T2/de not_active Expired - Lifetime
- 1996-06-19 CA CA002225286A patent/CA2225286C/en not_active Expired - Lifetime
- 1996-06-19 US US08/973,902 patent/US6083518A/en not_active Expired - Lifetime
- 1996-06-19 PT PT96921197T patent/PT833611E/pt unknown
- 1996-06-19 WO PCT/SE1996/000806 patent/WO1997000670A1/en not_active Ceased
- 1996-06-19 EP EP96921197A patent/EP0833611B1/de not_active Expired - Lifetime
- 1996-06-20 ZA ZA965237A patent/ZA965237B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1008774A1 (en) | 1999-05-21 |
| NZ311208A (en) | 1999-03-29 |
| PT833611E (pt) | 2002-01-30 |
| CA2225286C (en) | 2003-06-10 |
| SE9502244D0 (sv) | 1995-06-20 |
| ES2118677T3 (es) | 2001-10-16 |
| JPH11508250A (ja) | 1999-07-21 |
| WO1997000670A1 (en) | 1997-01-09 |
| ZA965237B (en) | 1997-01-09 |
| US6083518A (en) | 2000-07-04 |
| DK0833611T3 (da) | 2001-10-08 |
| EP0833611B1 (de) | 2001-08-22 |
| ES2118677T1 (es) | 1998-10-01 |
| AU6247396A (en) | 1997-01-22 |
| EP0833611A1 (de) | 1998-04-08 |
| JP4020331B2 (ja) | 2007-12-12 |
| DE69614689T2 (de) | 2002-06-27 |
| DE833611T1 (de) | 1999-01-07 |
| DE69614689D1 (de) | 2001-09-27 |
| AU695622B2 (en) | 1998-08-20 |
| CA2225286A1 (en) | 1997-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69614689D1 (de) | Zusammensetzung, die ein in einem glasbildenden träger gelösten wirkstoff enthalt und ein verfahren zu deren herstellung | |
| ATE204162T1 (de) | Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix | |
| FI103091B1 (fi) | Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi | |
| IS3966A (is) | Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine | |
| ATE152092T1 (de) | Salpetersäureester mit pharmazeutischer wirkung und verfahren zu deren herstellung | |
| DE3880762D1 (de) | Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung. | |
| ATE179886T1 (de) | Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung | |
| HUP9802814A3 (en) | Selective beta3 adrenergic agonists, pharmaceutical compositions containing them, process for producing them and their use | |
| ATE145649T1 (de) | Kardioaktive 17-aryl und 17-heterozyklyl-14 beta- 5alpha-androstane, androstene und androstadiene, ein verfahren zu ihrer herstellung und pharmazeutische präperate davon | |
| DE59510042D1 (de) | 2,2-dichloralkancarbonsäuren, verfahren zu ihrer herstellung diese enthaltende arzneimittel, und ihre verwendung zur behandlung der insulinresistenz | |
| DE69215595D1 (de) | Isochinolin-5-yl-Sulfonsäureamide, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
| ATE160344T1 (de) | Heterozyklische alkylamine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten | |
| PT801559E (pt) | Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama | |
| DE69112849D1 (de) | Wässrige phospholipidvesikeldispersion, verfahren zu deren herstellung sowie deren verwendung. | |
| ATE56707T1 (de) | Imidazolverbindungen, verfahren zu deren herstellung und deren pharmazeutische zusammensetzungen. | |
| ATE144510T1 (de) | N-(isochinolein-5-yl)-sulfonyl azazykloalkane, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| DE59607683D1 (de) | Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| ATE252371T1 (de) | Verfahren für die herstellung einer biologisch aktiven zusammensetzung | |
| DE3576154D1 (de) | 5-cyanopyridine-2-diazohydroxide, basische salze und verfahren zu ihrer herstellung und anwendung. | |
| DE3671444D1 (de) | Biologisch aktive substanz, girolline genannt, extrahiert aus dem schwamm pseudaxinyssa cantharella, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE58908775D1 (de) | 2-Halogensubstituierte N-Indolylethyl-sulfonsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln. | |
| ATE32063T1 (de) | Iminosulfonamide und verfahren zu ihrer herstellung, die pharmazeutische praeparate solche verbindungen enthalten, sowie die verbindungen zur verwendung. | |
| DE3764330D1 (de) | 2,2;6,6-diethylen-3-oxo-17alpha-pregn-4-en-21, 17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharm. praeparate. | |
| DE3887626D1 (de) | 2-Oxa-isocephem-Verbindungen, diese enthaltende Zusammensetzungen und Verfahren zu deren Herstellung. | |
| DE3576155D1 (de) | Diazohydroxypyrazinverbindungen, verfahren zu deren herstellung und verwendung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner |